Globus Medical, Inc.'s stock has surged due to a successful execution of the NuVasive deal and three consecutive guidance hikes, boosting investor confidence and valuation. The $3.1 billion ...

AngioDynamics’ shares have lost 8.9% year to date against the industry’s 6.7% growth. Globus Medical, carrying a Zacks Rank ...

The medical device maker reported big growth in revenue and earnings, driven by strong product sales and a recent major ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style ...

JMP Securities analyst David Turkaly has reiterated their neutral stance on GMED stock, giving a Hold rating on November 11. David Turkaly has ...

Operator Welcome to Globus Medical's third quarter 2024 earnings call. At this time, all lines will be on mute and a Q&A ...

Physicians Regional gave FOX 4's Collier County Community Correspondent Mahmoud Bennett an exclusive look at how the new ...

Morgan Stanley raised the firm’s price target on Globus Medical (GMED) to $83 from $74 and keeps an Equal Weight rating on the shares. The company reported “solid” Q3 topline and bottom-line beats, ...

Globus Medical, Inc.'s ( NYSE:GMED ) recent soft profit numbers didn't appear to worry shareholders, as the stock ...

Amalgamated Bank trimmed its position in Globus Medical, Inc. (NYSE:GMED – Free Report) by 5.4% in the third quarter, ...

Audubon, PA-based Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company currently has its ...

Globus Medical and NuVasive's merger marked its first year on Sept. 1, Globus' CEO Dan Scavilla said in a Nov. 5 earnings call.